Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) Director Arthur S. Kirsch bought 45,000 shares of Aralez Pharmaceuticals stock in a transaction that occurred on Wednesday, March 15th. The stock was bought at an average cost of $2.27 per share, for a total transaction of $102,150.00. Following the purchase, the director now owns 149,109 shares in the company, valued at approximately $338,477.43. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) traded up 4.44% during midday trading on Monday, reaching $2.35. The company had a trading volume of 3,998,815 shares. Aralez Pharmaceuticals Inc has a 52-week low of $2.05 and a 52-week high of $6.80. The company’s market capitalization is $153.93 million. The company’s 50 day moving average is $3.88 and its 200-day moving average is $4.58.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last announced its quarterly earnings results on Monday, March 13th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.26) by $0.11. Aralez Pharmaceuticals had a negative net margin of 211.76% and a negative return on equity of 65.67%. The firm earned $20 million during the quarter, compared to analyst estimates of $21.86 million. During the same quarter in the previous year, the business posted ($0.40) EPS. Aralez Pharmaceuticals’s revenue for the quarter was up 233.3% compared to the same quarter last year. Equities analysts expect that Aralez Pharmaceuticals Inc will post ($1.07) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)

Your IP Address:

Several large investors have recently made changes to their positions in ARLZ. Norges Bank purchased a new stake in shares of Aralez Pharmaceuticals during the fourth quarter valued at approximately $665,000. Armistice Capital LLC raised its stake in shares of Aralez Pharmaceuticals by 35.0% in the fourth quarter. Armistice Capital LLC now owns 2,836,000 shares of the company’s stock valued at $12,507,000 after buying an additional 736,000 shares during the last quarter. Glacier Peak Capital LLC raised its stake in shares of Aralez Pharmaceuticals by 122.6% in the fourth quarter. Glacier Peak Capital LLC now owns 102,400 shares of the company’s stock valued at $452,000 after buying an additional 56,400 shares during the last quarter. JW Asset Management LLC raised its stake in shares of Aralez Pharmaceuticals by 2.5% in the fourth quarter. JW Asset Management LLC now owns 2,680,140 shares of the company’s stock valued at $11,820,000 after buying an additional 65,000 shares during the last quarter. Finally, Tiger Legatus Capital Management LLC raised its stake in shares of Aralez Pharmaceuticals by 1.3% in the fourth quarter. Tiger Legatus Capital Management LLC now owns 1,985,000 shares of the company’s stock valued at $8,754,000 after buying an additional 25,000 shares during the last quarter. Institutional investors own 44.01% of the company’s stock.

Separately, Chardan Capital reduced their target price on Aralez Pharmaceuticals from $10.00 to $5.50 and set a “buy” rating on the stock in a research note on Wednesday, March 15th.

Aralez Pharmaceuticals Company Profile

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

5 Day Chart for NASDAQ:ARLZ

Receive News & Ratings for Aralez Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.